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Abstract 
Background: Advances in next-generation sequencing (NGS) technologies allow 
comprehensive studies of genetic diversity over the entire genome of human cytomegalovirus 
(HCMV), a significant pathogen for immunocompromised individuals. 
Methods: NGS was performed on target-enriched sequence libraries prepared directly from a 
variety of clinical specimens (blood, urine, breast-milk, respiratory samples, biopsies and 
vitreous humor) obtained longitudinally or from different anatomical compartments from 20 
HCMV-infected patients (renal transplant recipients, stem cell transplant recipients and 
congenitally infected children). 
Results: De novo assembled HCMV genome sequences were obtained for 57/68 sequenced 
samples. Analysis of longitudinal or compartmental HCMV diversity revealed various 
patterns: no major differences were detected among longitudinal, intra-individual blood 
samples from 9/15 patients and in most of the patients with compartmental samples, whereas 
a switch of the major HCMV population was observed in six individuals with sequential 
blood samples and upon compartmental analysis of one patient with HCMV retinitis. Variant 
analysis revealed additional aspects of minor virus population dynamics and antiviral 
resistance mutations. 
Conclusions: In immunosuppressed patients, HCMV can remain relatively stable or undergo 
drastic genomic changes that are suggestive of the emergence of minor resident strains or de 
novo infection. 
 
 
Key words: Next-generation sequencing, immunocompromised, human cytomegalovirus 
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Introduction 
Human cytomegalovirus (HCMV) contributes significantly to morbidity and mortality in 
immunocompromised patients, especially after transplantation, as well as in congenitally 
infected children. Primary HCMV infection or reactivation of latent HCMV can result in 
acute illness with end-organ manifestations such as retinitis, hepatitis, pneumonitis or 
enterocolitis [1]. The frequency and severity of HCMV disease in transplant recipients is 
influenced by risk factors such as donor and recipient HCMV serostatus or antiviral 
prophylaxis [2, 3]. 
HCMV (species Human betaherpesvirus 5) has a double-stranded DNA genome of 
approximately 236 kbp containing >170 open reading frames (ORFs) encoding functional 
proteins [4]. Most of the genome exhibits little variability among strains, although several 
hypervariable genes exist; in addition, recombination contributes to HCMV variability [5-12]. 
The picture of HCMV diversity within an individual host is complicated by the fact that prior 
infections with multiple strains, de novo infections and reactivation of latent virus can occur. 
The role of genome variation in HCMV pathogenesis is not well understood [13-15], although 
numerous studies have tried to characterize HCMV diversity and its clinical impact by PCR-
based genotyping of selected ORFs [16-18]. 
The high resolution provided by next-generation sequencing (NGS) has made it possible to 
study diversity across the entire HCMV genome [4, 8, 12, 19]. Several groups have applied 
NGS approaches to sequencing whole HCMV genomes, albeit mostly employing cell-culture 
passaged isolates or amplicon sequencing [6, 10, 12, 20-22]. Here, we employed a target 
enrichment approach to sequence directly from clinical samples, since this offers the 
advantage that the sequences obtained are more likely to represent accurately the original viral 
population than those obtained by using previous approaches [23]. We present an analysis 
based on sequence data obtained from sequential time points or different anatomical 
compartments from 20 HCMV-infected, immunocompromised patients. 
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Methods  
Patients and specimens 
A total of 68 archival, HCMV-positive clinical specimens were obtained from 20 patients for 
which real-time quantitative PCR (qPCR) for HCMV had been requested: whole blood 
(n=49), plasma (n=5), urine (n=3), breast milk (n=2), vitreous humor (n=1), tissue biopsies 
(n=4; from gut or liver) or respiratory material (n=4). Samples originated from four children 
with (congenital) HCMV disease (including breast milk from two of the children’s mothers), 
eight renal transplant recipients (RTRs) and eight haematopoietic stem cell transplant 
recipients (SCTRs). For 15/20 patients, blood samples obtained longitudinally at various time 
points were available (2-8 time points per patient; median 120 days (range 17-383) between 
first and last samples). Clinical data were retrieved from medical records. This descriptive 
study was approved by the institutional review board of Hannover Medical School (no. 2527-
2014). Table 1 shows an overview of patient demographics, clinical data and sample types. 
HCMV monitoring by qPCR (or pp65 antigenemia assay) was performed according to the 
procedures followed in individual transplant units. Antiviral treatment with ganciclovir, 
foscarnet or cidofovir and, in a few cases, maribavir, leflunomide or donor lymphocyte 
infusions were given at the physicians’ discretion (pre-emptively or triggered by signs or  
symptoms of HCMV infection). RTRs usually received antiviral prophylaxis depending on 
the risk constellation. 
 
Nucleic acid extraction and viral load quantitation 
Extraction of DNA from 200 µl clinical material and HCMV qPCR (calibrated to the WHO 
standard; limit of detection 500 IU/ml) were performed as described previously [24]. The 
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HCMV genome input concentration was calculated as IU (approximately equivalent to 
genome equivalents) per sequencing library. 
 
Next-generation sequencing 
DNA was sheared by sonication, and sequencing libraries were prepared (KAPA library 
preparation kit, KAPA Biosystems, Wilmington, USA) as described [25], with few 
modifications. Briefly, fragmented DNA was end-repaired, A-tailed and ligated to NEBnext 
Illumina adaptors (New England Biolabs, Ipswich, USA). After PCR pre-amplification (6-14 
cycles), up to 750 ng of DNA was target-enriched for HCMV fragments (SureSelect XT kit, 
Agilent, CA, USA). RNA probes for the bait library were designed on the basis of 64 
complete HCMV genome sequences available to us  in April 2014 (details available from A. 
Davison). HCMV-enriched libraries were indexed using TruGrade oligonucleotides 
(Integrated DNA Technologies), amplified (KAPA real-time library amplification kit), 
multiplexed, and sequenced on a MiSeq (Illumina) using reagent kit v3 to generate 2 x 300 
base paired-end reads. 
 
Assembly of HCMV genome sequences 
Bowtie2 v2.2.6 [26] was used to map reads to the UCSC hg19 human reference genome and 
these reads were then discarded. The remaining reads were subjected to quality assessment 
and adaptor trimming using FastQC and Trim Galore v0.4 
(http://www.bioinformatics.babraham.ac.uk/projects), retaining reads of quality score ≥20 and 
length >130 bp. Contigs were assembled de novo by using SPAdes v3.6 [27], and ordered 
against a version of the HCMV reference strain Merlin genome (GenBank AY446894.2) 
lacking the long and short terminal repeats (TRL and TRS) by using Scaffold_builder [28], 
abacas [29] or CLC Genomics Workbench v8 (Qiagen, 
https://www.qiagenbioinformatics.com/). Gaps were closed (GapFiller v1-10 [30]), potential 
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assembly errors corrected by iterative mapping (ICORN2 [31]), and genome annotations were 
transferred from HCMV strain Merlin (RATT [32]). Subsequent analyses were performed by 
using the resulting sample-specific consensus sequences ("major genome type"), lacking TRL 
and TRS, having assessed sequence quality by careful inspection of read alignments. The 
presence of multiple HCMV strains in the original specimen that likely arose by independent 
infection events (whether by co-infection, serial infection or reactivation) was assessed 
initially by mapping reads against the genotype-specific sequences of selected hypervariable 
genes (UL73, UL74, UL139 and UL146) characterised previously from a wide range of 
independent patients [5, 8, 33] (data not shown), and subsequently by calculating the level of 
nucleotide diversity by variant analysis. A control experiment was performed to validate this 
protocol (Figure S1). 
Selected complete HCMV genome sequences from patients infected by a single strain were 
deposited in GenBank ( KY123649-KY123653). 
 
Phylogenetic analysis 
A multiple sequence alignment of sample-specific consensus sequences was constructed 
(MAFFT v7 [34]). A neighbor-joining tree was constructed by using MEGA6 [35], applying 
the Kimura 2-parameter method with 500 bootstrap replicates and complete deletion of 
gapped sites. Overall mean distance and pairwise distance comparisons (p-distance) were 
performed (MEGA6) with one representative sample (n=20) from each patient or the whole 
dataset (n=57) with complete deletion of gapped sites. 
 
Variant analysis 
Duplicate reads presumably resulting from two or more PCR-derived copies of the same 
HCMV-DNA fragment were removed from each dataset by using Picard-v2.3.0 
Ac
ce
pt
ed
 M
an
us
cr
ipt
 8 
(https://github.com/broadinstitute/picard). Variants (SNPs and indels) were identified by 
using the low frequency variant detector function in CLC Genomics Workbench. 
The dynamics of variants over time were tracked by aligning sequence reads from different 
time points from a patient against the consensus sequence from the initial time point and 
performing variant calling. Variants were considered valid under the following conservative 
criteria: overall read depth ≥50, average basecall quality ≥20, forward/reverse read balance 
0.3-0.5 and variant frequency ≥2% (i.e. the relative frequency of a variant at a particular 
position). Variants detected within homopolymer regions or internal repeats (IRL/IRS) were 
excluded. Variants were plotted using custom R scripts by position in the HCMV genome and 
frequency at each time point. Variants present at >50% were taken to indicate a switch in the 
major HCMV genome type compared to the initial time point. In addition, the frequency 
distribution of variant alleles was visualised in frequency histograms. 
Antiviral resistance mutations were identified by using published definitions [36]. 
 
 
Results 
Next-generation sequencing of HCMV directly from clinical specimens 
To characterize HCMV diversity among samples collected sequentially or from different 
anatomical compartments, NGS was performed on DNA extracted from a set of 68 different 
clinical specimens from 20 immunocompromised patients by using target-enrichment. The 
median HCMV input per library was 1.8 x 10
4
 IU (range 1.0 x 10
3
 to 9.5 x 10
5
) for whole 
blood and 1.1 x 10
5
 IU (range 5.0 x 10
2
 to 3.9 x 10
6
) for other specimens. The range of 
percentage of HCMV reads in the enriched libraries was 0.03-88.8%. Consensus HCMV 
genomes were assembled from 57 sequenced samples, achieving an average coverage of 
99.94% (range 98.67-100%). An average read depth was obtained of 17-5,450 (median 359) 
for whole blood and 113-5,663 (median 2,932) for other specimens. Assembly of consensus 
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sequences for nine whole blood samples and one breast milk sample was not feasible due to 
low coverage, probably because of low HCMV input (range 5.0 x 10
2
 to 1.8 x 10
4
 IU per 
library). Assembly of data from one blood sample failed due to infection with two strains in 
approximately equal proportions. 
 
Interstrain diversity and phylogenetic analysis of major HCMV genome types 
The average interstrain nucleotide diversity calculated from the consensus sequence of one 
sample from each patient was 0.022 (i.e. any two HCMV strains differed by an average of 
2.193%). Phylogenetic analysis of all sample-specific consensus sequences obtained 
longitudinally or from different compartments (Figure 1) sorted the patients into two groups: 
those in whom one genome type was consistently dominant (Child1, Child2, Child3, Child4, 
RTR2, RTR4, RTR5, RTR9, RTR10, RTR11, SCTR2, SCTR4 and SCTR12) and those in 
whom the dominant genome type switched during the course of infecton (RTR6 among two 
compartments, and RTR1, RTR3, SCTR1, SCTR3, SCTR8 and SCTR11 among sequential 
samples). In the latter group, nucleotide diversity between the initial and final time points was 
0.008-0.026, indicating that in some patients the HCMV population after the switch differed 
from that before the switch to a similar extent to HCMV strains in two different individuals 
(Table 1). 
 
Genetic diversity among longitudinal samples  
The different clustering patterns of consensus sequences obtained from the same patient 
prompted an investigation of the level of within-host diversity for samples with sufficient read 
depth. For each patient, the HCMV population diversity was assessed by mapping the read 
data from each sample against the consensus sequence from the initial time point. Various 
patterns of within-host diversity were apparent (Table 1). 
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A switch in the major genome type over time was observed in 6/15 patients. For example, in 
SCTR1 at day 224 after transplantation, with the ultimately dominant genome type being 
detectable at low frequency in the initial sample at day 91 (Figure 2). In this sample, a 
multiple infection was detected by variant analysis of the initial time point data set against its 
own consensus sequence: 3982 intra-host variants with a median frequency of 7% (range 2-
25%) were detected. In the second blood sample (sampled 35 days later) and in the last blood 
sample, the median variant frequency increased to 36% (range 2-46%) and 83% (range 5-
100%), respectively. Similarly, a complete switch of the major genome type between the first 
and last samples was observed in SCTR11 within 104 days (Figure S2). In SCTR8, 4284 
(median frequency 8%, range 2-29%) and 6661 variants (median frequency 52%, range 2-
98%) were present at the initial and last time points, respectively. Interestingly, these variants 
segregated into two clusters, with a frequency range of 25-62% and of 85-95%, respectively 
(Figure 3). This indicated the emergence of a new dominant genome type at the second time 
point (which was already detected at the initial time point at low frequency) accompanied by 
an additional (minor) population perhaps arising due to reactivation. One or more of these 
additional populations may have been donor-derived in view of the D+/R+ serostatus 
constellation. 
Changes of the dominant HCMV genome type in patients RTR1, RTR3 and SCTR3 were also 
observed, with nucleotide diversity values between the initial and final time points of 0.011, 
0.019 and 0.008, respectively. However, because of low read depth in some samples, variant 
analysis could not always be interpreted with confidence. Nevertheless, based on the 
consensus sequence analysis, RTR1 showed an unusal diversity pattern among samples 
collected from two major reactivation episodes, with major differences in particular within the 
RL11 gene family (which contains several hypervariable members) and the US6 gene family, 
these regions being reminiscent of sequences contributed by independent strains (Figure 4). 
This suggests that the genome type emerging in the second reactivation episode (day 380 after 
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transplantation) may have resulted from intra-host recombination or from re-infection with, or 
reactivation of, a closely related strain. 
Finally, switches in the major genome type were not detected in the other nine patients with 
longitudinal samples (e.g. Figure S3), although some contained minor populations indicating 
multiple strain infections (Figure S4). 
 
HCMV diversity between anatomical compartments  
The major HCMV genome types from different anatomical compartments in the same patient 
were highly similar or identical to each other in blood and urine (blood and bronchoalveolar 
lavage in one case). These patients included the congenitally infected children (including  a 
corresponding breast milk sample from one mother) and most of the transplant recipients 
(Table 1). However, similar to the situation in sequential blood samples, minor populations 
likely corresponding to multiple strain infections were detected in a few patients.  
One impressive exception was patient RTR6, who suffered from full-blown HCMV retinitis 
occurring 8 years after renal transplantation. The major HCMV genome type from vitreous 
humor demonstrated major differences in comparison with the corresponding blood 
compartment. Using the consensus genome from blood as a reference, a total of 1000 variants 
(frequency 2-100% (median 84%)) were detected in the vitreous body compartment (Figure 
5A-B). A total of 731 variants were present at >50% (nonsynonymous=145, 
synonymous=435 and non-coding=151) and located mostly in the region containing genes 
UL69-UL99 (Figure 5C). Generally, synonymous substitutions were more common than 
nonsynonymous ones, although UL73 (glycoprotein N) and UL74 (glycoprotein O) displayed 
high levels of nonsynonymous substitution.  
 
Antiviral resistance mutations  
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A total of 8/15 longitudinally sampled patients showed mutations associated with HCMV 
antiviral resistance in at least one sample, in either or both of genes UL54 or UL97. Child4, 
RTR4, RTR9 and RTR10 did not exhibit resistance mutations initially, but developed UL97 
mutations later (Table 1), whereas RTR3 showed a low frequency resistance mutation in 
UL97 (16%) at the initial time point, which later became dominant. (68%). SCTR11 and 
SCTR1 developed low-frequency resistance mutations (<40%) in UL54 in blood after a 
switch of the dominant HCMV population. Interestingly, a dominant UL54 resistance 
mutation (Glu756Gln) was detected in a gut biopsy from SCTR1 at day 244 (76% frequency), 
compared to the corresponding blood sample (39% frequency). 
In RTR1 (D+/R-), who underwent antiviral prophylaxis, UL97 resistance mutations were 
already present initially (day 166), but were lost by day 235 when the patient exhibited UL54 
resistance mutations (foscarnet treatment had been started at day 186). Following antiviral 
treatment (two cycles of cidofovir, followed by ganciclovir/valganciclovir) this patient 
became negative for HCMV-DNAaemia, and, in the second reactivation episode at day 472 
(no antiviral treatment at this time), no signs of UL54 or UL97 resistance were detected, 
suggesting emergence of another HCMV genome type or re-emergence of the parental 
genome type from the latent repository as a result of selection against the resistance mutants 
in the absence of drug selection. 
 
 
Discussion 
Due to the low abundance of HCMV-DNA in many clinical specimens, most NGS-based 
studies analysing the whole HCMV genome have involved sequencing strains isolated in cell 
culture or amplicons generated by PCR. Here, we sequenced HCMV directly from a variety 
of clinical specimens using a commercial target enrichment approach that has been applied 
previously to several pathogens, including herpesviruses and HCMV [12, 37, 38]. Our 
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carefully designed bait library, which included multiple viral genotypes, proved key to 
success, as this enabled us to cope with the full range of genome variation and obtain 
adequate read depths throughout the genome. Also, adaptations of standard library 
preparation techniques [25] enabled us to sequence complete HCMV genomes even for 
specimens with relatively low viral loads and high human genomic backgrounds (e.g. whole 
blood). Current limitations of the method include relatively high costs and a limit of detection 
to yield complete HCMV genomes (here approximately 5000 IU/library for whole blood). In 
addition, low sequencing depth due to low viral input may hamper detailed variant analysis. 
The latter limitations can prove difficult for investigations using whole blood samples from 
transplant recipients, as high HCMV-DNAaemia is observed only in severe cases or after 
development of antiviral resistance. 
We obtained whole HCMV genomic data from 57 clinical specimens from 20 patients. Levels 
of interstrain diversity were similar to those estimates proposed previously [10]. Analysis of 
longitudinal HCMV diversity in blood samples showed a switch in the dominant HCMV 
population in 6/15 individuals. It is likely that these patients had multiple strain infections, 
and in most cases the strain that became dominant by the final time point was already 
detectable at the initial time point by variant analysis. A switch is probably due to a change in 
the relative levels of replication of strains in the multiple infection, as suggested by a study 
based on HCMV genotyping in lung transplant recipients [33]. An alternative explanation 
would be de novo infection. 
Patients with a longitudinal strain switch had a slightly longer observation time (Mann-
Whitney test, p=0.01) but no higher mortality than patients lacking a switch. It is unclear 
whether the former difference (likely due to the presence of resistance or prolonged, severe 
disease courses in high risk patients) might have facilitated the detection of a switch or, 
alternatively, whether a switch is more likely to lead to prolonged, and potentially more 
severe, episodes of HCMV-DNAemia. The latter hypothesis is supported by previous studies 
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on clinical outcome in immunocompromised patients, showing that multiple infections can be 
associated with higher viral loads, delayed clearance and increased HCMV disease rates, graft 
rejection and co-infections with other herpesviruses [16, 18, 39]. Multiple strain infections are 
common after transplantation (15-90%), and often found in the D+/R+ and, consistent with 
data from our cohort, D+/R- or D-/R+ patients, since both donor and recipient may have 
accumulated multiple strains prior to transplantation [15]. 
Longitudinal changes in the HCMV population might contribute to pathogenesis, for example 
via differential properties conferred by polymorphisms in viral glycoproteins, many of which 
are hypervariable and are known to contribute to immune evasion via antigenic variation [40]. 
In 4/6 patients showing a marked change of the HCMV population over time, the ultimately 
dominant genome type encoded variants of glycoprotein and immunomodulatory genes 
different from the initially dominant type. In contrast, the diversity observed upon a switch of 
the dominant population in RTR1 and SCTR3 was mostly observed only in genomic regions 
associated with immunomodulatory functions, which is more consistent with intra-host 
recombination events. Detection of these different patterns highlights an advantage of 
sequencing clinical material directly, rather than cell culture isolates, which, during 
passaging, tend to accumulate variations and mutations in certain glycoprotein and immune 
evasion genes [6, 8, 41]. 
From the analyses of HCMV population diversity among anatomical compartments, general 
compartmental differences in congenitally infected children and most of the transplant 
recipients were not observed. Recent studies on HCMV diversity in urine and blood from 
congenitally infected children have reported that multiple strain infections or 
compartmentalization between blood and urine are rarely detected in these patients [21, 42]. 
One exception in our study was patient RTR6, suffering from HCMV retinitis, who showed a 
remarkable diversity in the region encoding genes UL69-UL99, with glycoproteins gO 
(UL74) and gN (UL73) displaying the highest levels of non-synonymous substitutions. These 
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glycoproteins play important roles in tissue tropism and protect the virus from neutralizing 
antibodies [40, 43]. The presence of HCMV genotypes encoding different gB glycoproteins in 
vitreous humor and blood has been reported previously for AIDS patients with retinitis [44]. 
The mechanism of compartmentalization is not well understood, but could be attributed to 
selection of a particular strain (due to cellular tropism), bottlenecking of the viral population 
in the eye or de novo infection [45]. 
Antiviral resistance of HCMV is a severe clinical problem, especially for transplant recipients 
[46, 47]. In our study, 8/20 patients showed signs of UL97 or UL54 resistance mutations. In 
SCTR1, we observed the presence of a dominant UL54 resistance mutation in a gut biopsy 
but not in the corresponding blood sample. Such a compartmentalization of drug resistant 
HCMV has been reported previously as characterizing cerebrospinal fluid and blood in 
SCTRs [48, 49]. Although this was not the main aim of our study, NGS facilitates data 
mining in an unbiased fashion and allows the detection of low frequency events that are 
usually not detectable by Sanger sequencing. These advances could facilitate earlier detection 
of known resistance markers in patients at risk or novel mutations that are currently not 
accessible to routine diagnostics [50]. 
Our data show that the NGS of HCMV directly from a variety of diagnostic specimens is 
feasible and informative, providing new insights into viral diversity in longitudinally sampled 
patients. We found evidence of a switch of the major genome type in nearly half of the 
transplant recipients analysed, suggesting that recurrent HCMV-DNAaemia after 
transplantation does not necessarily reflect reappearance of the previously replicating strain, 
but rather the emergence of additional strains, possibly with variant biological properties, that 
were already present or acquired subsequently. This phenomenon could influence the 
development and course of HCMV disease, although it did not correlate with a fatal outcome 
in our relatively small patient cohort. Further investigations of the global variability patterns 
observed in clinical samples, as well as of the role of intra-host recombination and functions 
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of variants of key viral genes, are necessary to elucidate the role of HCMV diversity in 
pathogenesis. 
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Figure legends  
 
Figure 1: Phylogenetic analysis of HCMV consensus sequences. Sequences from six 
longitudinally sampled patients (RTR1, RTR3, SCTR1, SCTR3, SCTR8 and SCTR11) and 
one compartmentally analysed patient (RTR6) that clustered in different parts of the tree are 
shown in coloured font. Sequences from other patients that clustered together are shown in 
black font. RTR (triangle): renal transplant recipient; SCTR (circle): stem cell transplant 
recipient. 
 
Figure 2: Longitudinal and compartmental HCMV sequence diversity in stem cell 
transplant recipient SCTR1 (D-/R+). The HCMV consensus sequence from day 91 was 
used as a reference for variant calling. A: Variants are plotted by position on the HCMV 
genome and frequency at each time point. B: The frequency distribution of variants at each 
time point is illustrated in a histogram. Variants are binned at 1% intervals along the x-axis 
and the number of variants in each bin is shown on the y-axis. C: HCMV-DNA load (IU/ml; 
limit of detection 5 x 10
2
 IU/ml) in peripheral blood is plotted against the time after 
transplantation (days) during the follow-up period. Assembled consensus sequences and 
identified variants from different sampling time points of blood, nasal swab and intestinal 
biopsy samples are indicated by blue, lilac (# in panel C) and brown (* in panel C), 
respectively, in panels A-C.  
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Figure 3: Longitudinal HCMV sequence diversity in stem cell transplant recipient 
SCTR8 (D+/R+). The consensus sequence from day 55 was used as a reference for variant 
calling. A: Variant alleles are plotted by position on the HCMV genome and frequency at 
each time point. B: The frequency distribution of variants at each time point is plotted as 
explained in Figure 2. C: HCMV-DNA load (IU/ml) in peripheral blood is plotted against the 
time after transplantation (days) during the follow-up period. Blood samples for which 
HCMV consensus sequences were assembled are indicated by blue arrows. 
 
 
Figure 4: Longitudinal analysis of HCMV sequence diversity in renal transplant 
recipient RTR1 (D+/R-). A: HCMV-DNA load (IU/ml) in peripheral blood is plotted against 
the time after transplantation (days) during the follow-up period. Blood samples for which 
HCMV consensus sequences were assembled are indicated by blue arrows. B: Nucleotide 
diversity between consensus sequences from the initial (day 166) and final (day 549) time 
points was estimated in DnaSP v5.1 by using a sliding window approach with a 500 bp 
window size and a 100 bp  step size, and plotted according to genome position.  
 
Figure 5: HCMV compartmentalization in renal transplant recipient RTR6 suffering 
from HCMV retinitis. The consensus sequence from peripheral blood was used as a 
reference for variant calling. A: Variant alleles are plotted by position on the HCMV genome 
and frequency in each specimen. B: The frequency distribution of variants in each specimen is 
plotted as explained in Figure 2. Assembled consensus sequences and identified variants from 
peripheral blood and vitreous humor are indicated by blue and orange, respectively. C: 
Synonymous (dS) and non-synonymous (dN) dominant changes present in vitreous humor 
(>50% frequency) are depicted according to HCMV gene.  
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Figure legends (for greyscale in print version) 
 
Figure 1: Phylogenetic analysis of HCMV consensus sequences. Sequences from six 
longitudinally sampled patients (RTR1, RTR3, SCTR1, SCTR3, SCTR8 and SCTR11) and 
one compartmentally analysed patient (RTR6) that showed high inter-sample sequence 
diversity are labelled with a triangle (RTR) or circle (SCTR). RTR=renal transplant recipient; 
SCTR=stem cell transplant recipient. 
 
Figure 2: Longitudinal and compartmental HCMV sequence diversity in stem cell 
transplant recipient SCTR1 (D-/R+). The HCMV consensus sequence from day 91 was 
used as a reference for variant calling. A: Variants are plotted by position on the HCMV 
genome and frequency at each time point. B: The frequency distribution of variants at each 
time point is illustrated in a histogram. Variants are binned at 1% intervals along the x-axis 
and the number of variants in each bin is shown on the y-axis. C: HCMV-DNA load (IU/ml; 
limit of detection 5 x 10
2
 IU/ml) in peripheral blood is plotted against the time after 
transplantation (days) during the follow-up period. Assembled consensus sequences and 
identified variants from different sampling time points of blood (days: 91, 126, 194, 224, 231, 
and 245) are indicated by arrows with solid lines. The nasal swab (day 130) and intestinal 
biopsy (day 244) samples are indicated by arrows with dashed lines and labelled with # and *, 
respectively.
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Table 1: Patient demographics, clinical data and overview of sequencing results. 
Patient Gender, 
age 
(years) 
Underlying disease/HCMV 
manifestation 
D/R 
HCMV 
serostatus 
Outcome (days 
after 
transplantation  
or birth) 
Specimens (no. 
sequential blood 
samples) 
Time 
span of 
samples 
(days) 
Change of 
major HCMV 
population 
detected? 
Mean distance 
between intial and 
final timepoint or 
compartmentsa 
Multiple 
HCMV 
strain 
infection? 
HCMV antiviral resistance mutations detected 
(% and timepoints) 
Treatment 
Child-1 M, 0 
cCMV disease/microcephaly, 
dystrophy & hearing loss 
NA Alive (1203) 
Blood, urine, 
mother´s breast 
milk 
0 No 0.0000000000 No None GCV, VGCV 
Child-2 
twin-A 
F, 0 cCMV disease/hearing loss NA Alive (589) 
Blood, urine, 
mother´s breast 
milk 
1 No 0.0000000000 No None GCV, VGCV 
Child-3 
twin-B 
F, 0 cCMV disease/hearing loss NA Alive (786) Blood, urine 1 No 0.0000000000 No None GCV, VGCV 
Child-4 F, 0 Immunodeficiency/pneumonia NA Died (164) Blood (n=2), BAL 69 No 0.0000044904 No 
UL97: Met460Val (35.61% - day 161); Met460Ile (2.73% 
- day 161); His520Gln (45.46% - day 161); Leu595Ser 
(2.32% - day 161) 
GCV, FCV, 
leflunomide, CMV-
specific IgG 
RTR1  F, 68 
Renal transplanation/multiple 
reactivations 
D+/R- Alive (1460) Blood (n=6) 383 Yes 0.0110013965 Unclear 
UL97: Leu595Ser (70% - day 166, 25% - day 235); UL54: 
Leu545Ser (50% - day 235) 
VGCV, GCV, FCV 
RTR2  M, 70 
Renal transplanation /fever, graft 
rejection 
D+/R- Alive (1424) Blood (n=3) 173 No 0.0000000000 No 
 
GCV, VGCV 
RTR3  F, 62 
Renal transplanation/reactivation 
under prophylaxis 
D+/R- Alive (1311) Blood (n=3) 170 Yes 0.0191334492 Yes UL97: Met460Ile (16% - day 367; 68.06% - day 408) GCV 
RTR4  M, 62 
Renal 
transplanation/enterocolitis, 
hepatitis 
D+/R- Alive (670) Blood (n=3) 105 No 0.0000044904 No UL97: Leu595Phe (63.03% - day 355) GCV, VGCV 
RTR5 M, 77 
Renal transplanation/systemic 
diesease (liver, lung & GI-tract 
affected) 
D+/R- Alive (497) 
Blood, biopsy, 
BAL 
17 No 0.0000000000 No None GCV, FCV 
RTR6 M, 57 
Renal transplanation/HCMV 
retinitis 
D+/R+ Alive (no data) 
Vitreous body 
fluid, blood 
1 Yes 0.0032106116 Yes None GCV, VGCV 
RTR9 F, 52 
Renal and pancreas 
tranplanation/systemic disease, 
enterocolitis 
D+/R- Alive (1640) 
Blood (n=2), 
biopsy 
128 No 0.0000044904 No UL97: Leu595Ser (100% - day 310) GCV, VGCV 
RTR10 M, 68 
Renal transplanation/systemic 
disease 
D+R- Alive (2193) Blood (n=2) 120 No 0.0000000000 No 
UL97: Leu595Ser (18.10% - day 237); Lys599_Ser604del 
(60.18% - day 237) 
VGCV 
SCTR1 F, 52 
Allo-HSCT/persistent 
reactivation with systemic 
disease 
D-/R+ Died (792) 
Blood (n=8), nasal 
swab, biopsy 
263 Yes 0.0253750578 Yes 
UL54: Thr813Ser (7.46% - day 224, 22.86% - day 245); 
Ala809Val (4.48% - day 224); Glu756Gln (23.08% - day 
224, 29.82% - day 231, 75.94% - day 244b, 39.29% - day 
245); Ala834Pro (6.12% - day 231, 8.57% - day 245) 
GCV, FCV, CDV, 
DLI, maribavir 
SCTR2 M, 36 Allo-HSCT/HCMV pneumonia D-/R+ Alive (491) Blood (n=2), BAL 17 No 0.0000000000 Yes None 
GCV, FCV, CDV, 
VGCV 
SCTR3 F, 46 
Allo-HSCT 
(twice)/reactivations, hepatitis 
D+/R+ & 
D-/R+ 
Died (320) Blood (n=5) 184 Yes 0.0080646972 Yes None GCV, FCV 
SCTR4 F, 64 
Allo-HSCT/subclinical 
reactivations 
D-/R+ Died (254) Blood (n=2) 64 No 0.0000000000 No None GCV, FCV, CDV 
SCTR8 F, 36 Allo-HSCT/reactivations D+/R+ Died (314) Blood (n=3) 235 Yes 0.0256848931 Yes None FCV,CDV,DLI 
SCTR9 M, 43 
Allo-HSCT (twice)/systemic 
disease, hepatitis,duodenitis 
D+/R- Died (187) 
Blood (n=3), liver 
biopsy 
94 No 0.0000000000 Yes None GCV, FCV, CDV 
SCTR11 F, 36 Allo-HSCT/enterocolitis D-/R+ Alive 2153) Blood (n=3) 104 Yes 0.0252089143 Yes UL54: Val781Ile (15.05% - day 192) 
GCV, FCV, CDV, 
CMV-specific IgG, 
leflunomide 
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SCTR12 F, 0 
Congenital immunodeficiency, 
allo-HSCT/systemic disease 
with lung involvement 
D+/R+ Alive (2132) Blood (n=2) 84 No 0.0000000000 No None GCV, FCV 
ap-distance of HCMV genome sequences; bgut biopsy 
RTR=renal transplant recipient; SCTR=stem cell transplant recipient; cCMV=congenital CMV infection; allo-HSCT=allogeneic haematopoietic stem cell transplantation; D=donor; R=recipient; 
GCV=ganciclovir; VGCV=valganciclovir; FCV=foscarnet; CDV=cidofovir; DLI= donor lymphocyte infusion
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
 
 
